drugset / Trial / NCT01891851

A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers

NCT01891851

Phase 1 Completed 12 enrolled Tibotec Pharmaceuticals, Ireland
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug-drug interaction between steady-state concentrations of CYP3A4 or ritonavir and TMC435350 after its first and the last dose of the multiple dosing regimen and to explore the short term safety and tolerability of multiple doses of 200 mg of TMC435350 administered alone and in combination with 100 mg of ritonavir.

Timeline

Start
2007-10
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified 100 mg Oral
Subject Simeprevir Small molecule 200 mg Oral

Indications

No indication recorded.